Kezar Life Sciences Bilan de santé

Santé financière contrôle des critères 5/6

Kezar Life Sciences possède un total de capitaux propres de $134.0M et une dette totale de $10.3M, ce qui porte son ratio d'endettement à 7.7%. Son actif total et son passif total sont $164.1M et de $30.0M.

Informations clés

7.7%

Ratio d'endettement

US$10.26m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$148.39m
Fonds propres	US$134.05m
Total du passif	US$30.04m
Total des actifs	US$164.09m

Mises à jour récentes de la santé financière

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Dec 08

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Aug 15

Recent updates

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Dec 08

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Oct 03

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Aug 26

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Apr 05

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Mar 01

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Jan 25

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Dec 21

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

Dec 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de KZR ( $156.4M ) dépassent ses passifs à court terme ( $20.4M ).

Passif à long terme: Les actifs à court terme de KZR ( $156.4M ) dépassent ses passifs à long terme ( $9.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: KZR dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de KZR est passé de 0% à 7.7% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: KZR dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: KZR dispose d'une marge de trésorerie suffisante pour 1.7 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 23.4 % chaque année.

Kezar Life Sciences Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Kezar Life Sciences Regain Compliance with Nasdaq Listing Rule 5550(a)(2)

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement Required to Maintain Continued Listing on the Nasdaq Capital Market

Kezar Life Sciences, Inc. to Transfer Its Listing to the Nasdaq Capital Market

Kezar Life Sciences Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Recent updates

Kezar Life Sciences Regain Compliance with Nasdaq Listing Rule 5550(a)(2)

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement Required to Maintain Continued Listing on the Nasdaq Capital Market

Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. (NasdaqCM:KZR) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Kezar Life Sciences, Inc. (NasdaqCM:KZR) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $80.3 million.

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Life Sciences, Inc. Announces Cessation of Enrollment and Dosing in the Phase 2B Palizade Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences, Inc. Provides Business Update

Kezar Life Sciences, Inc. to Transfer Its Listing to the Nasdaq Capital Market

Kezar Life Sciences, Inc., Annual General Meeting, Jun 18, 2024

Consensus EPS estimates fall by 23%

Kezar Life Sciences Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Kezar Life Sciences, Inc. Announces CEO Changes

New minor risk - Market cap size

New minor risk - Share price stability

Price target decreased by 8.0% to US$15.33

Price target decreased by 7.7% to US$16.00

Price target decreased by 9.1% to US$16.67

Price target decreased to US$17.33

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Kezar Life Sciences, Inc. Presents Positive Complete Results from the Mission Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis At the American College of Rheumatology Convergence 2022

Kezar Life Sciences, Inc. Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting

Kezar Life Sciences, Inc. Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Price target increased to US$19.67

Kezar Life Sciences, Inc. Announces Positive Topline Results from the Mission Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

Kezar Life Sciences, Inc. Announces Executive Changes

Price target decreased to US$20.67

Kezar Life Sciences, Inc. Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis

Price target increased to US$22.67

Independent Director recently bought US$1.3m worth of stock

Independent Director exercised options and sold US$53k worth of stock

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Price target increased to US$20.67

Price target increased to US$17.67

Independent Director exercised options to buy US$238k worth of stock.

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

Kezar Life Sciences, Inc. Presents Results of the Completed MISSION Phase 1B Study of KZR-616 at EULAR 2021

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

New 90-day high: US$6.99

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

New 90-day high: US$6.00

Kezar Life Sciences, Inc. Provides Update on KZR-616: Selective Immunoproteasome Inhibitor and KZR-261: Protein Secretion Program

New 90-day high: US$5.20

Kezar Life Sciences, Inc. to Report Q2, 2020 Results on Aug 05, 2020

New 90-day low - US$4.36

Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from Russell 3000 Growth Index

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines